Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyclacel Pharmaceuticals (CYCC)
NASDAQ:CYCC
RESEARCH TOOLSreports
Holding CYCC?
Track your performance easily
Earnings Data
Report Date
Apr 01, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.29Last Year’s EPS
-$2.27Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -22.68%
|Next Earnings Date:Apr 01, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant progress in the clinical development of fadra and a strong financial position, despite some challenges in R&D tax credits and increased expenses for topogezotitib.Company Guidance
During the Cyclacel Q2 2024 earnings call, the company provided key updates on their precision medicine strategy, particularly focusing on fadra, an oral CDK2/9 inhibitor. Recruitment is progressing well in the 065-101 Phase II proof-of-concept study, with an enriched cohort targeting patients with CDKN2A and CDK NIB chromosomal abnormalities. Initial clinical activity results are expected in Q4 2024. Financially, Cyclacel reported cash equivalents of $6 million as of June 2024, with net cash used in operating activities amounting to $3.6 million for the first half of the year, indicating a decrease from $8.2 million in the same period of 2023. Research and development expenses for the quarter were $2 million, a reduction from $4.7 million in Q2 2023, with specific R&D expenses for fadra at $1.5 million, down from $3 million the previous year. The company anticipates that current cash resources will cover planned programs into the fourth quarter of 2024.Progress in Fadra Phase II Study
Cyclacel reported successful recruitment in the enriched cohort of their Phase II proof-of-concept study for fadra, with positive preliminary signals in heavily pretreated patients across various cancer types. Initial clinical activity is expected to be reported in Q4 2024.
Strong Financial Position
Cyclacel's cash equivalents increased to $6 million as of June 2024, compared to $3.4 million at the end of 2023. The company raised $6.3 million through financing activities.
Reduced Net Loss
Net loss for the quarter was reduced to $3.3 million compared to $5.5 million in the same period of 2023.
---
CYCC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CYCC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $0.41 | $0.45 | +9.76% |
| Aug 14, 2024 | $1.45 | $1.32 | -8.97% |
| May 14, 2024 | $2.84 | $2.44 | -14.08% |
| Mar 19, 2024 | $2.35 | $2.25 | -4.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cyclacel Pharmaceuticals (CYCC) report earnings?
Cyclacel Pharmaceuticals (CYCC) is schdueled to report earning on Apr 01, 2025, TBA Not Confirmed.
What is Cyclacel Pharmaceuticals (CYCC) earnings time?
Cyclacel Pharmaceuticals (CYCC) earnings time is at Apr 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CYCC EPS forecast?
CYCC EPS forecast for the fiscal quarter 2024 (Q4) is -$0.29.
---